Vaccines for cholesterol management

World Journal of Surgery

Volumn 31, Issue 4, 2007, Pages 690-694

  Rittershaus, Charles W ^a  

^a AVANT Immunotherapeutics Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADJUVANT; BETA LIPOPROTEIN CHOLESTEROL CONJUGATE; BOVINE SERUM ALBUMIN CHOLESTEROL CONJUGATE; CHOLESTEROL ESTER; CHOLESTERYL ESTER TRANSFER INHIBITOR 1; CHOLESTERYL ESTER TRANSFER INHIBITOR 2; DNA VACCINE; LOW DENSITY LIPOPROTEIN; OXIDIZED LOW DENSITY LIPOPROTEIN; UNCLASSIFIED DRUG; VACCINE; VAXIMMUNE;

ADJUVANT THERAPY; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CHOLESTEROL METABOLISM; CONFERENCE PAPER; DISEASE COURSE; NONHUMAN;

ANIMALS; ANTIBODY FORMATION; ATHEROSCLEROSIS; AUTOANTIBODIES; CHOLESTEROL; CHOLESTEROL ESTER TRANSFER PROTEINS; CLINICAL TRIALS; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; HUMANS; IMMUNOTHERAPY, ACTIVE; LIPID METABOLISM; LIPOPROTEINS; VACCINES;

EID: 33947622513     PISSN: 03642313     EISSN: 14322323     Source Type: Journal    
DOI: 10.1007/s00268-006-0759-0     Document Type: Conference Paper

References (33)

1. Murray CJ, Lopez AD. Mortality by cause for eight regions of the world: Global Burden of Disease Study. Lancet 1997;349:1269-1276.
2. Srivastava PK. Therapeutic cancer vaccines. Curr Opin Immunol 2006;18:201-205.
3. Nigam PK, Kerketta M. AIDS vaccine: present status and future challenges. Indian J Dermatol Venereol Leprol 2006;72:8-18.
4. Gero S, Farkas K, Gergely J, et al. [Inhibition of cholesterol arteriosclerosis following immunization by beta-lipoprotein; preliminary report]. Otorinolaringol Ital 1959;100:1119-1120.
5. Siegler PE. Some immunological aspects of atherosclerosis. Rev Atheroscler (Paris) 1967;9:(Suppl 1):199.
6. Bailey JM, Tomar R. Lipoprotein immunization and induced atherosclerosis in rabbits. 1. cockerel beta-lipoproteins as antigens. J Atheroscler Res 1965;5:203-214.
7. Gero S. Some data on the influence of cholesterol atherosclerosis by immunological means. Rev Atheroscler (Paris) 1967;9:(Suppl 1):194-198.
8. Virella G, Virella I, Leman RB, et al. Anti-oxidized low-density lipoprotein antibodies in patients with coronary heart disease and normal healthy volunteers. Int J Clin Lab Res 1993;23:95-101.
9. Salonen JT, Yla-Herttuala S, Yamamoto R, et al. Autoantibody against oxidised LDL and progression of carotid atherosclerosis. Lancet 1992;339:883-887.
10. Maggi E, Perani G, Falaschi F, et al. [Autoantibodies against oxidised low density lipoproteins in patients with coronary disease]. Presse Med 1994;23:1158-1162.
11. Puurunen M, Manttari M, Manninen V, et al. Antibody against oxidized low-density lipoprotein predicting myocardial infarction. Arch Intern Med 1994;154:2605-2609.
12. Bergmark C, Wu R, de Faire U, et al. Patients with early-onset peripheral vascular disease have increased levels of autoantibodies against oxidized LDL. Arterioscler Thromb Vasc Biol 1995;15:441-445.
13. Palinski W, Tangirala RK, Miller E, et al. Increased autoantibody titers against epitopes of oxidized LDL in LDL receptor-deficient mice with increased atherosclerosis. Arterioscler Thromb Vasc Biol 1995;15:1569-1576.
14. Ameli S, Hultgardh-Nilsson A, Regnstrom J, et al. Effect of immunization with homologous LDL and oxidized LDL on early atherosclerosis in hypercholesterolemic rabbits. Arterioscler Thromb Vasc Biol 1996;16:1074-1079.
15. Hansson GK, Libby P, Schonbeck U, et al. Innate and adaptive immunity in the pathogenesis of atherosclerosis. Circ Res 2002;91:281-291.
16. Fredrikson GN, Hedblad B, Berglund G, et al. Identification of immune responses against aldehyde-modified peptide sequences in apoB associated with cardiovascular disease. Arterioscler Thromb Vasc Biol 2003;23:872-878.
17. Shah PK, Chyu KY, Nilsson J. Immunotherapy for atherosclerosis: an emerging paradigm. Rev Cardiovasc Med 2004;5:194-203.
18. Shah PK, Chyu KY, Fredrikson GN, et al. Immunomodulation of atherosclerosis with a vaccine. Nat Clin Pract Cardiovasc Med 2005;2:639-646.
19. Shah PK, Chyu KY, Fredrikson GN, et al. Vaccination for atherosclerosis: a novel therapeutic paradigm. Expert Rev Vaccines 2004;3:711-716.
20. Hansson GK, Libby P. The immune response in atherosclerosis: a double-edged sword. Nat Rev Immunol 2006;6:508-519.
21. Fredrikson GN, Andersson L, Soderberg I, et al. Atheroprotective immunization with MDA-modified apo B-100 peptide sequences is associated with activation of Th2 specific antibody expression. Autoimmunity 2005;38:171-179.
22. Bailey JM, Bright R, Tomar R. Immunization with a synthetic cholesterol-ester antigen and induced atherosclerosis in rabbits. Nature 1964;201:407-408.
23. Bailey JM, Bright R, Tomar R, et al. Anti-atherogenic effects of cholesterol vaccination. Biochem Soc Trans 1994;22:433S.
24. Alving CR, Swartz GM Jr, Wassef NM, et al. Immunization with cholesterol-rich liposomes induces anti-cholesterol antibodies and reduces diet-induced hypercholesterolemia and plaque formation. J Lab Clin Med 1996;127:40-49.
25. Tardif JC. Prevention challenges: the era of atherosclerosis regression. Can J Cardiol 2006;22:(Suppl C):27-30.
26. Swenson TL, Hesler CB, Brown ML, et al. Mechanism of cholesteryl ester transfer protein inhibition by a neutralizing monoclonal antibody and mapping of the monoclonal antibody epitope. J Biol Chem 1989;264:14318-14326.
27. Bisgaier CL, Siebenkas MV, Hesler CB, et al. Effect of a neutralizing monoclonal antibody to cholesteryl ester transfer protein on the redistribution of apolipoproteins A-IV and E among human lipoproteins. J Lipid Res 1989;30:1025-1031.
28. Rittershaus CW, Miller DP, Thomas LJ, et al. Vaccine-induced antibodies inhibit CETP activity in vivo and reduce aortic lesions in a rabbit model of atherosclerosis. Arterioscler Thromb Vasc Biol 2000;20:2106-2112.
29. Davidson MH, Maki K, Umporowicz D, et al. The safety and immunogenicity of a CETP vaccine in healthy adults. Atherosclerosis 2003;169:113-120.
30. Gaofu Q, Rongyue C, Dan M, et al. Asparaginase display of human cholesteryl ester transfer protein (CETP) B cell epitopes for inducing high titers of anti-CETP antibodies in vivo. Protein Pept Lett 2006;13:149-154.
31. Gaofu Q, Jun L, Xiuyun Z, et al. Antibody against cholesteryl ester transfer protein (CETP) elicited by a recombinant chimeric enzyme vaccine attenuated atherosclerosis in a rabbit model. Life Sci 2005;77:2690-2702.
32. Gaofu Q, Jun L, Xin Y, et al. Vaccinating rabbits with a cholesteryl ester transfer protein (CETP) B-Cell epitope carried by heat shock protein-65 (HSP65) for inducing anti-CETP antibodies and reducing aortic lesions in vivo. J Cardiovasc Pharmacol 2005;45:591-598.
33. Gaofu Q, Dan M, Jie W, et al. Long-lasting specific antibodies against CETP induced by subcutaneous and mucosal administration of a 26-amino acid CETP epitope carried by heat shock protein 65 kDa in the absence of adjuvants. Vaccine 2004;22:3187-3194.